Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets (Q35130485)

6 August 2017

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets (English)

1 reference

6 August 2017

1 reference

irritable bowel syndrome

1 reference

H L Dupont

1

1 reference

PubMed ID

24665829

6 August 2017

language of work or name

English

0 references

publication date

25 March 2014

1 reference

Alimentary Pharmacology & Therapeutics

6 August 2017

1 reference

6 August 2017

39

1 reference

6 August 2017

10

1 reference

6 August 2017

1033-1042

1 reference

The impact of irritable bowel syndrome on health-related quality of life

6 August 2017

1 reference

Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role

21 January 2018

1 reference

Costs of irritable bowel syndrome in the UK and US.

21 January 2018

1 reference

21 January 2018

Irritable bowel syndrome

1 reference

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

Alterations in the intestinal microbiota and functional bowel symptoms

21 January 2018

1 reference

Targeted therapies for diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

Intestinal microbiota and its role in irritable bowel syndrome (IBS).

21 January 2018

1 reference

The indigenous gastrointestinal microflora

21 January 2018

1 reference

The normal intestinal microbiota.

21 January 2018

1 reference

Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.

21 January 2018

1 reference

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

Intestinal microbiota in functional bowel disorders: a Rome foundation report

21 January 2018

1 reference

Durable alteration of the colonic microbiota by the administration of donor fecal flora

21 January 2018

1 reference

Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis

21 January 2018

1 reference

Antibiotics for irritable bowel syndrome: rationale and current evidence

21 January 2018

1 reference

Inflammation and microflora

21 January 2018

1 reference

Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome.

21 January 2018

1 reference

Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome

21 January 2018

1 reference

Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome.

21 January 2018

1 reference

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls

21 January 2018

1 reference

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.

21 January 2018

1 reference

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease

21 January 2018

1 reference

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

21 January 2018

1 reference

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

21 January 2018

1 reference

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

The rationale and clinical effectiveness of probiotics in irritable bowel syndrome

21 January 2018

1 reference

Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews

21 January 2018

1 reference

IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation

21 January 2018

1 reference

Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

21 January 2018

1 reference

Consumption of fermented milk product with probiotic modulates brain activity

21 January 2018

1 reference

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study

21 January 2018

1 reference

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

21 January 2018

1 reference

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

21 January 2018

1 reference

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects

21 January 2018

1 reference

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

Biologic properties and clinical uses of rifaximin

21 January 2018

1 reference

Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

21 January 2018

1 reference

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study

21 January 2018

1 reference

The neurobiology of stress and gastrointestinal disease

21 January 2018

1 reference

The brain-gut axis in abdominal pain syndromes

21 January 2018

1 reference

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction

21 January 2018

1 reference

Principles and clinical implications of the brain-gut-enteric microbiota axis

21 January 2018

1 reference

Voices from within: gut microbes and the CNS.

21 January 2018

1 reference

The interplay between the intestinal microbiota and the brain

21 January 2018

1 reference

Linkage of gut microbiome with cognition in hepatic encephalopathy

21 January 2018

1 reference

The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice

21 January 2018

1 reference

The intestinal microbiota and chronic disorders of the gut.

21 January 2018

1 reference

Altered peripheral toll-like receptor responses in the irritable bowel syndrome

21 January 2018

1 reference

The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota

21 January 2018

1 reference

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

21 January 2018

1 reference

Mechanisms of hypersensitivity in IBS and functional disorders

21 January 2018

1 reference

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

21 January 2018

1 reference

Treatments targeting putative mechanisms in irritable bowel syndrome

21 January 2018

1 reference

Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12728

1 reference

6 August 2017

1 reference

PubMed ID

24665829